Granules India arm gets USFDA nod for Dofetilide capsules

Dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

Published On 2021-10-19 05:49 GMT | Update On 2023-10-11 09:40 GMT

Telangana: Granules India has recently announced that the US Food & Drug Administration (USFDA) has approved the Abbreviated New Drug Application (ANDA) filed by Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company, for Dofetilide Capsules, 125 mcg, 250 mcg, and 500 mcg.

It is bioequivalent to the reference listed drug product (RLD), Tikosyn Capsules, 125 meg, 250 mcg, and 500 mcg, of Pfizer Inc.

"This product would be manufactured at the GPI facility located in Chantilly, Virginia, USA and is expected to be launched shortly," the company said in a BSE filing.

Dofetilide capsules are indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. They are also indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

Granules now has a total of 45 ANDA approvals from US FDA (43 Final approvals and 2 tentative approvals). Dofetilide Capsule products had U.S. sales of approximately $39 million for the most recent twelve months ending in August 2021 according to IQVIA Health.

Tikosyn is a registered trademark of Pfizer, Inc.

In July, Granules Pharmaceuticals, Inc. (GPI), a wholly owned foreign subsidiary of the Company located in Chantilly, Virginia, USA had undergone a Pre-Approval Inspection (PAI) audit by the U.S. Food and Drug Administration (USFDA) from 21st June 2021 to 25th June 2021.

Read also: Granules India Arm Clears USFDA Audit

Granules India is an Indian pharmaceutical manufacturing company that was founded in 1984 named as Triton Laboratories located in Hyderabad, India.

Granules manufactures varieties of drugs including Paracetamol, Ibuprofen, Metformin, and Guaifenesin, on a large scale for customers in the domestic as well as international markets.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Granules India arm gets USFDA nod for Dofetilide capsules

Dofetilide capsules are indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

Similar News

After Cough Syrup Deaths, CDSCO Tightens Oversight on Drug Testing Compliance

Exemed Pharma's Empagliflozin-Vildagliptin Combo Rejected by CDSCO Panel Over Questionable Clinical Use

Ravenbhel Gets SEC Nod to Market Bilastine, Montelukast FDC, Phase IV Trial Mandated

Drugs Control Officials Caught Taking Rs 20,000 Bribe in Telangana

Contaminated Cough Syrup horror: Centre proposes license cancellation of Coldrif maker, Tamil Nadu FDA yet to act

Himachal, UP Join States Banning Coldrif Cough Syrup After MP Deaths

Toxic syrup tragedy: MP police hunt pharma co owner after child deaths

Not of Standard Quality: Gujarat orders suspension of production at two pharma cos